Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity

References

• 1 Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13(11), 1285–1306 (2012).
  CASGoogle Scholar
• 2 Dello Russo C, Lisi L, Lofaro A et al. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. Pharmacogenomics 12(4), 567–576 (2011).
  Google Scholar
• 3 Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58(1), 25–32 (2008).
  MedlineGoogle Scholar
• 4 Chen Y-T, Chung W-H, Hung S-I. HLA-B genotyping to detect carbamazepine-induced Stevens–Johnson syndrome: implications for personalizing medicine. Per. Med. 2, 225–237 (2005).
  Google Scholar
• 5 Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med. Genet. 12, 118 (2011).
  Medline CASGoogle Scholar
• 6 Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19(9), 704–709 (2009).
  Medline CASGoogle Scholar
• 7 Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134–4139 (2005).
  Medline CASGoogle Scholar
• 8 Saokaew S, Tassaneeyakul W, Maenthaisong R, Chaiyakunapruk N. Cost–effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS ONE 9(4), e94294 (2014).
  MedlineGoogle Scholar
• 9 Cristallo AF, Schroeder J, Citterio A et al. A study of HLA class I and class II 4-digit allele level in Stevens–Johnson syndrome and toxic epidermal necrolysis. Int. J. Immunogenet. 38(4), 303–309 (2011).
  Medline CASGoogle Scholar
• 10 Hetherington S, Mcguirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23(10), 1603–1614 (2001).
  Medline CASGoogle Scholar
• 11 Peyriere H, Guillemin V, Lotthe A et al. Reasons for early abacavir discontinuation in HIV-infected patients. Ann. Pharmacother. 37(10), 1392–1397 (2003).
  Medline CASGoogle Scholar
• 12 Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J. Antimicrob. Chemother. 59(4), 591–593 (2007).
  Medline CASGoogle Scholar
• 13 Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727–732 (2002).
  Medline CASGoogle Scholar
• 14 Perez Prior N, Rocher Milla A, Soler Company E, Flores Cid J, Sarria Chust B. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B•5701 allele]. Farmacia Hospitalaria 33(3), 155–160 (2009).
  MedlineGoogle Scholar
• 15 Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K et al. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. Pharmacogenomics 12(6), 809–814 (2011).
  CASGoogle Scholar
• 16 Sun HY, Hung CC, Lin PH et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J. Antimicrob. Chemother. 60(3), 599–604 (2007).
  Medline CASGoogle Scholar
• 17 Sousa-Pinto B, Pinto-Ramos J, Correia C et al. Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01. J. Allergy Clin. Immunol. 136(4), 1092.e3–1094.e3 (2015).
  Google Scholar
• 18 Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568–579 (2008).
  MedlineGoogle Scholar
• 19 Yeo SI. HLA-B•5801: utility and cost-effectiveness in the Asia-Pacific Region. Int. J. Rheum. Dis. 16(3), 254–257 (2013).
  MedlineGoogle Scholar
• 20 Kostenko L, Kjer-Nielsen L, Nicholson I et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens 78(1), 11–20 (2011).
  Medline CASGoogle Scholar
• 21 Maekawa K, Nishikawa J, Kaniwa N et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens–Johnson syndrome/toxic epidermal necrolysis in Japanese. Drug Metab. Pharmacokinet. 27(4), 447–450 (2012).
  Medline CASGoogle Scholar
• 22 Vidal C, Li J, Fulton R, Fernando SL. A polymorphism within the psoriasis susceptibility 1 candidate 1 (PSORS1C1) gene is not linked to HLA-B*58:01 in an Australian cohort. Drug Metab. Pharmacokinet. doi: 10.1016/j.dmpk.2015.08.007 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 23 Kwok J, Kwong KM. Loop-mediated isothermal amplification for detection of HLA-B*58:01 allele. Tissue Antigens 81(2), 83–92 (2013).
  Medline CASGoogle Scholar
• 24 Kwok J, Kwong KM. Detection of HLA-B•58:01, the susceptible allele for allopurinol-induced hypersensitivity, by loop-mediated isothermal amplification. Br. J. Dermatol. 168(3), 526–532 (2013).
  Medline CASGoogle Scholar
• 25 Martin AM, Nolan D, Mallal S. HLA-B•5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 65(6), 571–574 (2005).
  Medline CASGoogle Scholar
• 26 Giardina E, Stocchi L, Foti Cuzzola V et al. A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01. Electrophoresis 31(21), 3525–3530 (2010).
  Medline CASGoogle Scholar
• 27 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16(3), 1215 (1988).
  Medline CASGoogle Scholar
• 28 Cascella R, Stocchi L, Strafella C et al. Comparative analysis between saliva and buccal swabs as source of DNA: lesson from HLA-B*57:01 testing. Pharmacogenomics 16(10), 1039–1046 (2015).
  CASGoogle Scholar